354 Stock Overview A specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. More details
Rewards Risk Analysis See All Risk Checks Capture your thoughts, links and company narrative
Collegium Pharmaceutical, Inc. Competitors Price History & Performance
Summary of share price highs, lows and changes for Collegium Pharmaceutical Historical stock prices Current Share Price US$27.80 52 Week High US$38.60 52 Week Low US$27.40 Beta 0.81 1 Month Change -6.08% 3 Month Change -19.19% 1 Year Change 0% 3 Year Change 62.57% 5 Year Change 44.79% Change since IPO 99.33%
Recent News & Updates
Third quarter 2024 earnings released: EPS: US$0.29 (vs US$0.61 in 3Q 2023) Nov 08 Collegium Pharmaceutical, Inc. Announces Executive Changes, Effective November 12, 2024
Collegium Pharmaceutical, Inc. to Report Q3, 2024 Results on Nov 07, 2024 Oct 24
Executive VP & Chief Medical Officer recently sold €317k worth of stock Sep 19
Executive VP recently sold €697k worth of stock Sep 09
Collegium Pharmaceutical, Inc. Updates Financial Guidance for the Full Year 2024 Sep 05 See more updates
Third quarter 2024 earnings released: EPS: US$0.29 (vs US$0.61 in 3Q 2023) Nov 08 Collegium Pharmaceutical, Inc. Announces Executive Changes, Effective November 12, 2024
Collegium Pharmaceutical, Inc. to Report Q3, 2024 Results on Nov 07, 2024 Oct 24
Executive VP & Chief Medical Officer recently sold €317k worth of stock Sep 19
Executive VP recently sold €697k worth of stock Sep 09
Collegium Pharmaceutical, Inc. Updates Financial Guidance for the Full Year 2024 Sep 05
Second quarter 2024 earnings released: EPS: US$0.60 (vs US$0.38 in 2Q 2023) Aug 09
New minor risk - Share price stability Aug 06
Investor sentiment improves as stock rises 18% Jul 30
Collegium Pharmaceutical, Inc. Provides Net Product Revenues Guidance for the Second Quarter Ended June 30, 2024; Reaffirms Financial Guidance for the Full Year 2024 Jul 30
Collegium Pharmaceutical, Inc. (NasdaqGS:COLL) agreed to acquire Ironshore Therapeutics Inc. for approximately CAD 550 million. Jul 29
Collegium Pharmaceutical, Inc. to Report Q2, 2024 Results on Aug 08, 2024 Jul 26
Executive VP & Chief Commercial Officer recently sold €1.0m worth of stock May 29
Collegium Pharmaceutical, Inc. Reaffirms Earnings Guidance for the Full Year 2024 May 11
First quarter 2024 earnings released: EPS: US$0.86 (vs US$0.51 loss in 1Q 2023) May 10 Collegium Announces CEO Transition
Collegium Pharmaceutical, Inc. to Report Q1, 2024 Results on May 09, 2024 Apr 27
Collegium Pharmaceutical, Inc., Annual General Meeting, May 16, 2024 Apr 06
Investor sentiment improves as stock rises 17% Feb 29
Full year 2023 earnings released: EPS: US$1.43 (vs US$0.74 loss in FY 2022) Feb 23
Collegium Pharmaceutical, Inc. to Report Q4, 2023 Results on Feb 22, 2024 Feb 09
Collegium Pharmaceutical, Inc. Revises Earnings Guidance for the Full-Year of 2023 Nov 09
Collegium Pharmaceutical, Inc. Revises Earnings Guidance for the Full-Year of 2023 Nov 08
New major risk - Financial position Nov 08
New minor risk - Shareholder dilution Nov 03
Collegium Pharmaceutical, Inc. to Report Q3, 2023 Results on Nov 07, 2023 Oct 25
Collegium Pharmaceutical, Inc. Announces Extension of Nucynta Regulatory Exclusivity Through July 2026 Aug 25
Second quarter 2023 earnings released: EPS: US$0.38 (vs US$0.15 loss in 2Q 2022) Aug 04
Collegium Pharmaceutical, Inc. Reaffirms Earnings Guidance for the Year 2023 Aug 04 Collegium Pharmaceutical, Inc. to Report Q2, 2023 Results on Aug 03, 2023
Collegium Pharmaceutical, Inc. Reaffirms Product Revenues Guidance for Full-Year 2023 May 06
First quarter 2023 earnings released: US$0.51 loss per share (vs US$0.39 loss in 1Q 2022) May 05
Full year 2022 earnings released: US$0.74 loss per share (vs US$2.05 profit in FY 2021) Feb 24
Collegium Pharmaceutical, Inc. to Report Q4, 2022 Results on Feb 23, 2023 Feb 07 Collegium Pharmaceutical, Inc. Provides Earnings Guidance for the Year of 2023
Appeals Court Affirms Validity of Collegium's Belbuca(R) Patents Dec 23
Insufficient new directors Nov 16
Collegium Pharmaceutical, Inc. Provides Earnings Guidance for the Year of 2022 Nov 06
Third quarter 2022 earnings released: EPS: US$0.013 (vs US$0.23 in 3Q 2021) Nov 05
Collegium Pharmaceutical, Inc. to Report Q3, 2022 Results on Nov 03, 2022 Oct 21
Second quarter 2022 earnings released: US$0.15 loss per share (vs US$2.06 profit in 2Q 2021) Aug 05
Collegium Pharmaceutical, Inc. to Report Q2, 2022 Results on Aug 04, 2022 Jul 22
Investor sentiment improved over the past week Jun 28
First quarter 2022 earnings released: US$0.39 loss per share (vs US$0.45 profit in 1Q 2021) May 11
Insufficient new directors Apr 27 Collegium Pharmaceutical, Inc. Appoints Neil McFarlane to its Board of Directors
Collegium Pharmaceutical, Inc. Provides Revenue Guidance for the Year 2022 Apr 06
Collegium Pharmaceutical, Inc. Announces Master Settlement Agreement Resolving Pending Opioid-Related Litigation Mar 31
Full year 2021 earnings: EPS in line with expectations, revenues disappoint Feb 26
Full year 2021 earnings: EPS in line with expectations, revenues disappoint Feb 26
Collegium Pharmaceutical, Inc. Provides Earnings Guidance for the Year 2022 Feb 25
Investor sentiment improved over the past week Feb 16 Collegium Pharmaceutical, Inc. (NasdaqGS:COLL) entered into an agreement to acquire BioDelivery Sciences International, Inc. (NasdaqGS:BDSI) for approximately $580 million. Feb 16
Collegium Pharmaceutical, Inc. (NasdaqGS:COLL) entered into an agreement to acquire BioDelivery Sciences International, Inc. (NasdaqGS:BDSI) for approximately $580 million. Feb 15
Collegium Pharmaceutical, Inc. Announces Settlement Framework to Resolve All 27 Pending Opioid-Related Litigation Dec 29
Third quarter 2021 earnings released: EPS US$0.23 (vs US$0.33 in 3Q 2020) Nov 06
Executive VP & Chief Technical Officer Alison Fleming has left the company Oct 05
Collegium Pharmaceutical, Inc. (NasdaqGS:COLL) announces an Equity Buyback for $100 million worth of its shares. Aug 17
Second quarter 2021 earnings released: EPS US$2.06 (vs US$0.23 in 2Q 2020) Aug 08
Collegium Pharmaceutical, Inc. Provides Revenue Guidance for the Full Year 2021 Aug 08
Investor sentiment deteriorated over the past week Aug 07
Executive VP & CFO has left the company May 25
First quarter 2021 earnings released: EPS US$0.45 (vs US$0.013 in 1Q 2020) May 08
Investor sentiment deteriorated over the past week Mar 05
Full year 2020 earnings released: EPS US$0.78 (vs US$0.68 loss in FY 2019) Feb 27
Revenue misses expectations Feb 27
New 90-day high: €21.20 Feb 11
Investor sentiment improved over the past week Jan 19
New 90-day high: €20.00 Jan 18
New 90-day low: €14.80 Dec 23
Third quarter 2020 earnings released: EPS US$0.33 Nov 07
Revenue beats expectations Nov 07
New 90-day high: €18.40 Oct 10
Collegium Announces Settlement with Teva Resolving Xtampza ER Patent Litigation Oct 01
Collegium Pharmaceutical, Inc. Appoints Rita Balice-Gordon to Board of Directors Sep 26
New 90-day high: €16.90 Sep 22
New 90-day high - €16.80 Sep 07
Collegium Pharmaceutical, Inc. announced that it has received $35 million in funding from Pharmakon Advisors Aug 13
New 90-day low - €14.10 Jul 27 Shareholder Returns 354 DE Pharmaceuticals DE Market 7D -4.8% -0.3% -0.2% 1Y 0% -17.0% 7.0%
See full shareholder returns
Return vs Market: 354 underperformed the German Market which returned 7% over the past year.
Price Volatility Is 354's price volatile compared to industry and market? 354 volatility 354 Average Weekly Movement 6.2% Pharmaceuticals Industry Average Movement 5.5% Market Average Movement 4.9% 10% most volatile stocks in DE Market 11.7% 10% least volatile stocks in DE Market 2.4%
Stable Share Price: 354 has not had significant price volatility in the past 3 months compared to the German market.
Volatility Over Time: 354's weekly volatility (6%) has been stable over the past year.
About the Company Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain. The company was formerly known as Collegium Pharmaceuticals, Inc. and changed its name to Collegium Pharmaceutical, Inc. in October 2003.
Show more Collegium Pharmaceutical, Inc. Fundamentals Summary How do Collegium Pharmaceutical's earnings and revenue compare to its market cap? 354 fundamental statistics Market cap €912.16m Earnings (TTM ) €84.97m Revenue (TTM ) €574.74m
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) 354 income statement (TTM ) Revenue US$599.25m Cost of Revenue US$79.91m Gross Profit US$519.33m Other Expenses US$430.74m Earnings US$88.59m
Last Reported Earnings
Sep 30, 2024
Earnings per share (EPS) 2.75 Gross Margin 86.66% Net Profit Margin 14.78% Debt/Equity Ratio 420.9%
How did 354 perform over the long term?
See historical performance and comparison
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2024/12/27 00:45 End of Day Share Price 2024/12/27 00:00 Earnings 2024/09/30 Annual Earnings 2023/12/31
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources Collegium Pharmaceutical, Inc. is covered by 12 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution Louise Chen Cantor Fitzgerald & Co. Dana Flanders Guggenheim Securities, LLC Antonio Arce H.C. Wainwright & Co.
Show 9 more analysts 
